AIMS: The goal of this observational, single-cohort, pre-post study was to describe the association of tirzepatide with glycaemic control and weight loss in patients with type 2 diabetes (T2D) in a US commercially insured population.
MATERIALS AND METHODS: Using the Healthcare Integrated Research Database (HIRD®), members ≥18 years, diagnosed with T2D, initiating tirzepatide between 13 May 2022 and 31 January 2023, with ≥1 glycated haemoglobin (HbA1c) result around the index date and the end of the 6-month follow-up period were identified. Baseline demographics and antihyperglycaemic medication use and key outcomes (HbA1c and weight) at 6-month follow-up were assessed overall and in subgroups stratified by baseline glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use and HbA1c (<7% and ≥7%) level.
RESULTS: The cohort of 2247 identified patients was primarily non-Hispanic White, female (58%), 54 years old, 54% had GLP-1 RA at baseline, 59% had an HbA1c ≥7% at baseline and 61% had overweight/obesity. At 6-month follow-up, a majority of the cohort (69%) had an HbA1c <7%, which was higher (77%) in the GLP-1 RA naïve subgroup. Mean change in weight was: -6.3 kg for the overall cohort; -7.1 kg in patients with baseline HbA1c <7%; and -8.1 kg in the GLP-1 RA naïve subgroup.
CONCLUSION: In this observational, single-cohort study, at 6-month follow-up, patients with T2D initiating tirzepatide showed HbA1c and weight reductions; more pronounced HbA1c reductions occurred in GLP-1 RA naïve patients or those with baseline HbA1c ≥7%, while more weight loss was observed among GLP-1 RA naïve patients or those with baseline HbA1c <7%.
